Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903701 | 0.88 | CYP1A2 (0.42) | CYP1A2ADH1BADH1CADH1AADH4 | |
| SCHEMBL11903815 | 0.86 | SIGMAR1 (0.42) | CYP1A2ADH1BADH1CADH1AADH4 | |
| SCHEMBL7452334 | 0.81 | ADH1B (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL7909190 | 0.77 | CYP1A2 (0.44) | CYP1A2SIGMAR1BACE1KMT2A | |
| SCHEMBL7909192 | 0.77 | CYP1A2 (0.44) | CYP1A2SIGMAR1BACE1KMT2A | |
| SCHEMBL6153538 | 0.70 | CYP1A2 (0.48) | CYP1A2SIGMAR1CTSDBACE1CTSL | |
| SCHEMBL5450869 | 0.70 | CYP1A2 (0.48) | CYP1A2SIGMAR1CTSDBACE1CTSL | |
| SCHEMBL9173367 | 0.70 | CETP (0.33) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL15355135 | 0.70 | CYP1A2 (0.48) | CYP1A2SIGMAR1CTSDBACE1CTSL | |
| SCHEMBL11903774 | 0.69 | SHBG (0.32) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | claimed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | claimed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | claimed |
| US-5643906-A | LOWERING INTRAOCULAR PRESSURE FOR TREATMENT OF GLAUCOMA | G.D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | claimed |
| US-5484937-A | ANGIOTENSIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | claimed |
| EP-0579766-A1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-01-26 | — | — | EP | claimed |
| US-5175180-A | Antagonist, antagonism | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | claimed |
| EP-2487148-B1 | CYCLIC COMPOUND, METHOD FOR PRODUCING SAME, RADIATION SENSITIVE COMPOSITION, AND METHOD FOR FORMING RESIST PATTERN | MITSUBISHI GAS CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8829247-B2 | Cyclic compound, method of producing the same, radiation sensitive composition, and method of forming resist pattern | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120251947-A1 | CYCLIC COMPOUND, METHOD OF PRODUCING THE SAME, RADIATION SENSITIVE COMPOSITION, AND METHOD OF FORMING RESIST PATTERN | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2487148-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING SAME, RADIATION SENSITIVE COMPOSITION, AND METHOD FOR FORMING RESIST PATTERN | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-08-15 | — | — | EP | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251947-A1 | CYCLIC COMPOUND, METHOD OF PRODUCING THE SAME, RADIATION SENSITIVE COMPOSITION, AND METHOD OF FORMING RESIST PATTERN | MRE11, SLC11A2, CROCC | CYP1A2 1428/4885ADH1B 2640/4885ADH1C 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.